Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1076

—

74def769-174d-5e86-b0ae-3dff8582cacb

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.527
  • G2M_CHECKPOINT+0.483
  • MITOTIC_SPINDLE+0.258
  • APICAL_SURFACE+0.228
  • PROTEIN_SECRETION+0.190
  • MTORC1_SIGNALING+0.164
  • PEROXISOME+0.162
  • TGF_BETA_SIGNALING+0.148
  • ESTROGEN_RESPONSE_EARLY+0.125
  • MYC_TARGETS_V1+0.103

Top 10 suppressed

  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.359
  • ALLOGRAFT_REJECTION-0.328
  • ANGIOGENESIS-0.320
  • OXIDATIVE_PHOSPHORYLATION-0.304
  • COAGULATION-0.282
  • COMPLEMENT-0.241
  • INTERFERON_GAMMA_RESPONSE-0.241
  • WNT_BETA_CATENIN_SIGNALING-0.232
  • IL6_JAK_STAT3_SIGNALING-0.229
  • INFLAMMATORY_RESPONSE-0.228

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1ERR2278878
head-neck@1
——0.852
2MNG1184
mng-umap@100
——0.829
3MNG1222
mng-umap@100
——0.798
4TCGA-A2-A1G4-01A-11R-A13Q-07
breast-umap@18
—B0.787
5MDT-AP-1191
medullo-epn-umap@date-based
MedMedulloblastoma0.779
6TCGA-E2-A155-01A-11R-A12D-07
breast-umap@18
—B0.773
7TCGA-OR-A5KO-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.768
8TCGA-AQ-A04H-01B-11R-A10J-07
breast-umap@18
—B0.767
9SRR8942988
bladder-landscape@3
——0.754
10MNG970
mng-umap@100
——0.736

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.527Inavolisib— uncovered
G2M_CHECKPOINT0.483Inavolisib— uncovered
MITOTIC_SPINDLE0.258Inavolisib— uncovered
APICAL_SURFACE0.228Temsirolimus— uncovered
PROTEIN_SECRETION0.190Remibrutinib— uncovered
MTORC1_SIGNALING0.164Inavolisib— uncovered
PEROXISOME0.162Idelalisib— uncovered
TGF_BETA_SIGNALING0.148Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.125Inavolisib— uncovered
MYC_TARGETS_V10.103Inavolisib— uncovered
DNA_REPAIR0.095Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.090Idelalisib— uncovered
SPERMATOGENESIS0.081Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.072Remibrutinib— uncovered
UV_RESPONSE_DN0.070Inavolisib— uncovered
ANDROGEN_RESPONSE0.063Inavolisib— uncovered
BILE_ACID_METABOLISM0.052Inavolisib— uncovered
APICAL_JUNCTION0.044Inavolisib— uncovered
P53_PATHWAY0.036Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.033Inavolisib— uncovered